235 related articles for article (PubMed ID: 1672042)
1. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
Lee MT; Liebow C; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
4. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
Liebow C; Lee MT; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2244-8. PubMed ID: 1672452
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
6. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
[TBL] [Abstract][Full Text] [Related]
7. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
8. Membrane receptors for peptides in experimental and human pancreatic cancers.
Fekete M; Zalatnai A; Comaru-Schally AM; Schally AV
Pancreas; 1989; 4(5):521-8. PubMed ID: 2573055
[TBL] [Abstract][Full Text] [Related]
9. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Liebow C; Reilly C; Serrano M; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(6):2003-7. PubMed ID: 2564678
[TBL] [Abstract][Full Text] [Related]
12. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
Paz-Bouza JI; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
Fekete M; Wittliff JL; Schally AV
J Clin Lab Anal; 1989; 3(3):137-47. PubMed ID: 2569034
[TBL] [Abstract][Full Text] [Related]
14. Alterations in receptor-mediated kinases and phosphatases during carcinogenesis.
Crean DH; Liebow C; Lee MT; Kamer AR; Schally AV; Mang TS
J Cancer Res Clin Oncol; 1995; 121(3):141-9. PubMed ID: 7713985
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
Szende B; Zalatnai A; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
Szende B; Srkalovic G; Schally AV; Lapis K; Groot K
Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771
[TBL] [Abstract][Full Text] [Related]
17. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Kadar T; Redding TW; Ben-David M; Schally AV
Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
[TBL] [Abstract][Full Text] [Related]
18. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
Zalatnai A; Schally AV
Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
Torres-Aleman I; Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
[TBL] [Abstract][Full Text] [Related]
20. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
